AbbVie’s Skyrizi sustains clinical and endoscopic outcomes in ulcerative colitis for up to three years

AbbVie will present 20 inflammatory bowel disease research abstracts at UEG Week, Oct. 17-20, 2026, in Barcelona. Skyrizi maintained clinical and endoscopic improvements in ulcerative colitis for up to three years; Rinvoq sustained Crohn's disease outcomes for approximately four years. Real-world findings linked switching from TNF inhibitors to Rinvoq with fewer IBD-related hospitalizations or surgeries than cycling to another TNF inhibitor. Upcoming Phase 3 AFFIRM presentations will expand findings on subcutaneous Skyrizi induction and maintenance in Crohn's disease. Investigational dual-targeting therapy ABBV-466 will feature in a Phase 2a presentation on endoscopic remission in moderate-to-severe Crohn's disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via (Ref. ID: 202610170200PR_NEWS_USPR_____CG73550) on October 17, 2026, and is solely re